PHVS Pharvaris N.V.
Price Chart
Executive Summary
Pharvaris announced the publication of positive Phase 2 data from its CHAPTER-1 and RAPIDe-1 trials in The Lancet Haematology, showing deucrictibant's efficacy and safety as both a prophylactic and on-demand oral treatment for hereditary angioedema (HAE). The results support its potential as a first-in-class oral B2 receptor antagonist for end-to-end HAE management, with Phase 3 topline data expected in Q3 2026.
Actionable Insight
Investors should monitor the upcoming Phase 3 CHAPTER-3 topline data in Q3 2026 as the next major catalyst; successful results could drive significant upside given the lack of oral options in HAE and strong Phase 2/3 signals to date.
Key Facts
- Phase 2 CHAPTER-1 trial showed statistically significant reduction in HAE attack frequency with deucrictibant for prophylaxis.
- Phase 2 RAPIDe-1 trial demonstrated statistically significant reduction in attack severity and faster symptom relief for on-demand treatment.
- Deucrictibant is an oral bradykinin B2 receptor antagonist, positioning it as a potential first-in-class oral therapy for both prevention and acute treatment of HAE.
- Topline data from pivotal Phase 3 RAPIDe-3 trial already confirmed faster symptom relief and single-capsule resolution in most attacks.
- Marketing authorization applications for deucrictibant immediate-release capsule are being prepared, with NDA submission expected in first half of 2026.
- Deucrictibant has orphan drug designation in the U.S., EU, and Switzerland.
Financial Impact
Potential blockbuster revenue if approved, given deucrictibant's dual indication and oral convenience in a chronic, high-cost rare disease market.
Risk Factors
- Phase 3 data may not replicate Phase 2 results, particularly in larger, more diverse populations.
- Regulatory delays or rejections despite strong data, especially given the novelty of the oral B2 antagonist mechanism.
- Competition from existing injectable therapies and emerging oral kallikrein inhibitors.
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3259646 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
May 29, 2026
11d ago
|
Press Release
| $30.16 $31.09 | ▲ +3.08% | ▲ +5.61% | $31.60 (+4.77%) |
|
May 26, 2026
14d ago
|
Insider Cluster
| $29.47 $30.14 | ▲ +2.27% | ▲ +1.80% | $31.60 (+7.23%) |
|
May 26, 2026
14d ago
|
Insider Cluster
| $29.47 $30.14 | ▼ −2.27% | ▼ −1.80% | $31.60 (−7.23%) |
|
May 22, 2026
18d ago
|
Insider Cluster
| $29.68 $29.10 | ▼ −1.95% | ▼ −3.63% | $31.60 (+6.47%) |
|
May 21, 2026
19d ago
|
144
| $29.68 $29.10 | ▼ −1.95% | ▼ −3.61% | $31.60 (+6.47%) |
|
May 20, 2026
20d ago
|
Insider Cluster
| $30.54 $30.16 | ▼ −1.24% | ▼ −3.09% | $31.60 (+3.47%) |
|
May 20, 2026
20d ago
|
144
| $30.54 $30.16 | ▼ −1.24% | ▼ −3.09% | $31.60 (+3.47%) |
|
May 19, 2026
21d ago
|
Insider Cluster
| $29.45 $29.86 | ▲ +1.39% | ▼ −0.41% | $31.60 (+7.30%) |
|
May 12, 2026
28d ago
|
Press Release
| $32.94 $28.95 | ▼ −12.11% | ▼ −10.95% | $31.60 (−4.07%) |
|
May 11, 2026
29d ago
|
6-K
| $31.25 $28.81 | ▼ −7.81% | ▼ −7.89% | $31.60 (+1.12%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access